Triatomic Q2 2025 Private
The Q2 2025 update letter from Triatomic Capital, dated July 31 2025, provides investors with a comprehensive view of market conditions, strategic observations, and fund activities. It notes that AI continues to accelerate across sectors, with increasing investor optimism, while life‑science and biotech face funding cuts, regulatory uncertainty, and a prolonged trough of disillusionment. The letter highlights macro‑level IPO and M&A activity (US$44.4 B in IPO value and US$75.7 B in venture‑backed M&A Y/Y growth), and discusses two core themes: (1) the fragmentation of foundational‑model companies as early AI oligopolies break down, with new entrants, reduced model stickiness, and emerging competition between model labs and their customers; and (2) the deteriorating environment for biotech, driven by a 41 % NIH budget cut, a 15 % cap on indirect cost recovery, and leadership turnover at the FDA. It reports a portfolio of 15 companies (31 % engineered biology, 31 % next‑gen compute, 22 % automated economy, 10 % engineered materials, 5 % new energy), outlines deal‑flow statistics (168 opportunities reviewed, 61 meetings, 12 advanced diligences, 6 closes), and details recent investments and KPIs for each portfolio company. The fund plans to call an additional 8‑10 % of commitments in August and anticipates several follow‑on rounds. Team composition remains unchanged, with a note on Jeff Huber’s recent podcast appearance. The letter concludes with logistical information about the AGM, contact details, and extensive legal disclosures.
Topics
AI Market Momentum and Investor Sentiment in Q2 2025
Overview of macro‑level AI trends, including sector‑wide optimism, IPO and M&A activity, and the shift from training‑heavy to inference‑heavy compute demand.
Biotech and Life‑Science Sector Downturn
Examination of policy‑driven challenges: 41 % NIH budget cut, 15 % cap on indirect cost recovery, visa freezes, FDA leadership turnover, and their impact on biotech funding and exits.
Portfolio Composition and Sector Allocation
Snapshot of the 15‑company portfolio with sector percentages (engineered biology, next‑gen compute, automated economy, engineered materials, new energy) and the distinction between core and non‑core investments.
Deal‑Flow Metrics and Recent Investment Activity
Quantitative overview of opportunities reviewed, meetings held, diligences, and closed deals, plus specific recent investments (e.g., Chalk AI, quantum computing startup, D‑Matrix Series C).
Company‑Level KPI Updates
Individual progress reports for portfolio companies (Manifold Bio, Chemify, Lyten, D‑Matrix, Elegen, Teleo, MatX, iPronics, Coworker.ai, Chalk) covering fundraising, product milestones, revenue growth, and strategic partnerships.
Fund Capital Deployment Outlook
Plan to call an additional 8‑10 % of capital commitments in August, expected follow‑on rounds, and the pipeline of upcoming investments in next‑gen compute and automated economy.
Team Update and Thought Leadership
Statement that the team composition is unchanged, with a note on Jeff Huber’s podcast appearance discussing his experience at Google and GRAIL.